Related Experiment Video
Updated: Sep 24, 2025

CD Spectroscopy to Study DNA-Protein Interactions
Published on: February 10, 2022
NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon
Yiannis Drosos1, Jacquelyn A Myers1, Beisi Xu2
1Division of Molecular Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Abstract:
Disruption of antagonism between SWI/SNF chromatin remodelers and polycomb repressor complexes drives the formation of numerous cancer types. Recently, an inhibitor of the polycomb protein EZH2 was approved for the treatment of a sarcoma mutant in the SWI/SNF subunit SMARCB1, but resistance occurs. Here, we performed CRISPR screens in SMARCB1-mutant rhabdoid tumor cells to identify genetic contributors to SWI/SNF-polycomb antagonism and potential resistance mechanisms. We found that loss of the H3K36 methyltransferase NSD1 caused resistance to EZH2 inhibition. We show that NSD1 antagonizes polycomb via cooperation with SWI/SNF and identify co-occurrence of NSD1 inactivation in SWI/SNF-defective cancers, indicating in vivo relevance. We demonstrate that H3K36me2 itself has an essential role in the activation of polycomb target genes as inhibition of the H3K36me2 demethylase KDM2A restores the efficacy of EZH2 inhibition in SWI/SNF-deficient cells lacking NSD1. Together our data expand the mechanistic understanding of SWI/SNF and polycomb interplay and identify NSD1 as the key for coordinating this transcriptional control.
Insights
Loss of NSD1 disrupts the balance between SWI/SNF and polycomb complexes, causing resistance to EZH2 inhibitors in cancer. Restoring H3K36me2 levels re-sensitizes cells to EZH2 inhibition.
Area of Science:
- Cancer Biology
- Epigenetics
- Chromatin Remodeling
Background:
- Disruption of SWI/SNF chromatin remodelers and polycomb repressor complexes contributes to various cancers.
- EZH2 inhibitors are approved for SMARCB1-mutant sarcoma, but resistance is a challenge.
Purpose of the Study:
- Identify genetic factors in SWI/SNF-polycomb antagonism and EZH2 inhibitor resistance.
- Elucidate the role of NSD1 in SWI/SNF-polycomb interplay and cancer development.
Main Methods:
- CRISPR screens in SMARCB1-mutant rhabdoid tumor cells.
- Assays to assess EZH2 inhibition efficacy and H3K36me2 levels.
- Analysis of co-occurrence of NSD1 inactivation in SWI/SNF-defective cancers.
Main Results:
- Loss of NSD1 confers resistance to EZH2 inhibition by disrupting SWI/SNF-polycomb antagonism.
- NSD1 inactivation is found in SWI/SNF-defective cancers, suggesting in vivo relevance.
- Inhibition of KDM2A restores EZH2 inhibitor efficacy in NSD1-deficient cells by modulating H3K36me2.
Conclusions:
- NSD1 is a key regulator of the SWI/SNF-polycomb axis and a determinant of EZH2 inhibitor response.
- Targeting H3K36me2 demethylases may overcome resistance to EZH2 inhibitors in SWI/SNF-mutant cancers.
Related Concept Videos
Inheritance of Chromatin Structures
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Co-activators and Co-repressors
Regulation of Nuclear Protein Sorting
Master Transcription Regulators

